MyFinsight
Home
Blog
About
Contact
Download
Download image
Proceeds from sale of
convertible notes, net of...
$139,049K
Proceeds from the royalty
agreement, net of issuance...
$21,670K
Issuance of common stock
from equity...
$1,228K
Issuance of common stock
from employee stock...
$694K
Sales and maturities
of marketable...
$105,364K
Net cash provided by
financing activities
$162,641K
Net cash provided by
(used in) investing...
$18,684K
Canceled cashflow
$86,680K
Net increase
(decrease) in cash, cash...
$97,873K
Canceled cashflow
$83,452K
Non-cash interest
expense and...
$11,796K
Stock-based compensation
expense
$11,415K
Prepaid expenses and
other assets
-$10,778K
Accounts payable
$4,191K
Fair value
adjustment to derivative...
-$3,426K
Impairment of right of use
assets
$1,190K
Depreciation and
amortization
$969K
Deferred revenue
$643K
Non cash operating
lease expense
$572K
Purchases of marketable
securities
$84,784K
Acquisition of property and
equipment
$1,707K
Capitalized website
development costs
$189K
Net cash used in
operating activities
-$81,621K
Effect of exchange rate
changes
-$1,831K
Canceled cashflow
$44,980K
Net loss
-$109,524K
Research and development
tax credit...
$4,809K
Accrued expenses and
other liabilities
-$3,828K
Inventory
$3,428K
Accounts receivable, net
$2,593K
Realized gain from sale of
marketable securities
$1,227K
Amortization of (discount)
premium on marketable...
-$637K
Foreign currency
exchange loss (gain)
$555K
Back
Back
Cash Flow
source: myfinsight.com
KalVista Pharmaceuticals, Inc. (KALV)
KalVista Pharmaceuticals, Inc. (KALV)